Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
对使用 AZD7442（Tixagevimab/Cilgavimab）早期门诊治疗 COVID-19 后 SARS-CoV-2 新兴变异株的分析（TACKLE 试验）
期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-023-00882-2
Kijak, Gustavo H; Ahani, Bahar; Arbetter, Douglas; Chuecos, Fernando; Gopalakrishnan, Vancheswaran; Beloor, Jagadish; Brady, Tyler; Nguyen, Amy; Roe, Tiffany L; Schuko, Nicolette; Zhang, Tianhui; Hobbs, F D Richard; Padilla, Francisco; Kelly, Elizabeth J; Montgomery, Hugh; Streicher, Katie
